ARCA biopharma Inc

For the period ended Dec 31, 2023. Filed Feb 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 1, 2024

ORKA$104.56+1.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

BALANCE SHEETS

	As of December 31,
	2023	2022
(in thousands, except shareand per share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$37,431	$42,445
Other current assets	161	254
Total current assets	37,592	42,699
Right-of-use asset - operating	247	343
Property and equipment, net	10	25
Other assets	12	18
Total assets	$37,861	$43,085
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$362	$334
Accrued compensation and employee benefits	100	173
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)	175	625
Total current liabilities	637	1,132
Operating lease liability, net of current portion	204	280
Total liabilities	841	1,412
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022	—	—
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2023 and 2022; 14,501,143 and 14,410,143 shares issued and outstanding at December 31, 2023 and 2022, respectively	14	14
Additional paid-in capital	225,747	225,061
Accumulated deficit	(188,741)	(183,402)
Total stockholders’ equity	37,020	41,673
Total liabilities and stockholders’ equity	$37,861	$43,085

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.